SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index

Go back to SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index

SAB Biotherapeutics Added to NASDAQ Biotechnology Index

December 20, 2021 6:00 AM UTC

SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, effective prior to market open on Monday, December 20, 2021.

The NASDAQ... More